Literature DB >> 15925447

Administration of glutamate into the spinal cord at extracellular concentrations reached post-injury causes functional impairments.

Guo-Ying Xu1, Michael G Hughes, Liping Zhang, Lisa Cain, David J McAdoo.   

Abstract

In vivo experiments addressing the role of released glutamate in damage caused by neurotrauma seldom administer glutamate itself because it usually produces relatively little damage when administered into central nervous system (CNS) tissue in vivo. However, because of recent observations that glutamate administered into the spinal cord at the levels attained following spinal cord injury (SCI) kills neurons and oligodendrocytes, we tested the effects of administering glutamate at those concentrations on locomotor function. The Basso-Beattie-Bresnahan (BBB) test and activity box measures demonstrated that those glutamate concentrations produce lasting functional impairments. Several parameters provided by the activity box provided sensitive measures of the degree of post-SCI impairment, demonstrating their substantial potential for evaluating outcomes of SCI. Results obtained also enhance evidence that glutamate toxicity contributes to secondary damage following SCI and suggest that damage to white matter is an important contributor to such damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925447     DOI: 10.1016/j.neulet.2005.04.100

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Reduction in expression of the astrocyte glutamate transporter, GLT1, worsens functional and histological outcomes following traumatic spinal cord injury.

Authors:  Angelo C Lepore; John O'Donnell; Andrew S Kim; Eun Ju Yang; Alisha Tuteja; Amanda Haidet-Phillips; Colin P O'Banion; Nicholas J Maragakis
Journal:  Glia       Date:  2011-08-31       Impact factor: 7.452

2.  Spatial and temporal changes in promoter activity of the astrocyte glutamate transporter GLT1 following traumatic spinal cord injury.

Authors:  Angelo C Lepore; John O'Donnell; Joseph F Bonner; Courtney Paul; Mark E Miller; Britta Rauck; Robert A Kushner; Jeffrey D Rothstein; Itzhak Fischer; Nicholas J Maragakis
Journal:  J Neurosci Res       Date:  2011-04-12       Impact factor: 4.433

3.  Transplantation of glial progenitors that overexpress glutamate transporter GLT1 preserves diaphragm function following cervical SCI.

Authors:  Ke Li; Elham Javed; Tamara J Hala; Daniel Sannie; Kathleen A Regan; Nicholas J Maragakis; Megan C Wright; David J Poulsen; Angelo C Lepore
Journal:  Mol Ther       Date:  2014-12-10       Impact factor: 11.454

4.  Human iPS cell-derived astrocyte transplants preserve respiratory function after spinal cord injury.

Authors:  Ke Li; Elham Javed; Daniel Scura; Tamara J Hala; Suneil Seetharam; Aditi Falnikar; Jean-Philippe Richard; Ashley Chorath; Nicholas J Maragakis; Megan C Wright; Angelo C Lepore
Journal:  Exp Neurol       Date:  2015-07-26       Impact factor: 5.330

5.  Glutamate-induced losses of oligodendrocytes and neurons and activation of caspase-3 in the rat spinal cord.

Authors:  G-Y Xu; S Liu; M G Hughes; D J McAdoo
Journal:  Neuroscience       Date:  2008-03-07       Impact factor: 3.590

Review 6.  An update on spinal cord injury research.

Authors:  He-Qi Cao; Er-Dan Dong
Journal:  Neurosci Bull       Date:  2012-11-03       Impact factor: 5.203

Review 7.  Opioid administration following spinal cord injury: implications for pain and locomotor recovery.

Authors:  Sarah A Woller; Michelle A Hook
Journal:  Exp Neurol       Date:  2013-03-15       Impact factor: 5.330

Review 8.  Microdialysis in central nervous system disorders and their treatment.

Authors:  David J McAdoo; Ping Wu
Journal:  Pharmacol Biochem Behav       Date:  2008-03-10       Impact factor: 3.697

9.  Potential Therapeutic Targets for PPARgamma after Spinal Cord Injury.

Authors:  Dana M McTigue
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

Review 10.  PPAR agonists as therapeutics for CNS trauma and neurological diseases.

Authors:  Shweta Mandrekar-Colucci; Andrew Sauerbeck; Phillip G Popovich; Dana M McTigue
Journal:  ASN Neuro       Date:  2013-12-18       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.